Abselion's US Leap: UK Innovator Targets Biotech Hub with New Tech

CAMBRIDGE, MA – March 09, 2026 – In a strategic move signaling significant global ambition, UK-based life sciences firm Abselion has established its first US subsidiary in the heart of the world's most concentrated biotechnology hub: Cambridge, Massachusetts. The new base of operations is located within The Engine, an incubator and accelerator built by the Massachusetts Institute of Technology (MIT) specifically to nurture 'Tough Tech' companies poised to solve complex global challenges. This expansion across the Atlantic is more than a geographical move; it represents a calculated push to embed Abselion's pioneering biomolecule quantification technology into the critical North American drug discovery and development ecosystem.

Abselion's arrival in the US follows a period of significant momentum. The company, founded in 2017, recently secured a £6.6 million Series A funding round led by M Ventures, the strategic corporate venture capital arm of Merck. This investment was explicitly earmarked to fuel the commercialization of its flagship Amperia™ platform and support this crucial international expansion. By planting a flag in Cambridge, Abselion gains direct access to a dense network of potential customers and partners, from world-renowned academic institutions to the headquarters of global pharmaceutical giants and hundreds of innovative biotech startups.

"Our vision is to make high-quality quantification more accessible through closer international collaboration," stated Dr. Ruizhi Wang, CEO and Founder of Abselion, in a recent announcement. "Establishing a US subsidiary marks an important milestone in Abselion’s growth, strengthening our ability to operate across key life science markets globally... A formal presence there demonstrates our commitment to supporting long-term adoption of our protein quantification systems."

Revolutionizing Quantification with the Amperia Platform

The excitement surrounding Abselion's expansion centers on the promise of its Amperia™ protein quantification system. The technology aims to solve a persistent bottleneck in biologics research and development: the need for rapid, reliable, and accessible measurement of biomolecules like antibodies, proteins, and adeno-associated viruses (AAVs) used in gene therapies.

Traditionally, scientists have relied on methods like the Enzyme-Linked Immunosorbent Assay (ELISA), a workhorse technique that, while effective, can take hours or even days to produce results. ELISA is also notoriously labor-intensive and can be susceptible to variability, especially when working with the complex or 'crude' samples common in early-stage research and bioprocess development. At the other end of the spectrum, high-end technologies like surface plasmon resonance (SPR) offer exquisite sensitivity but are expensive, require specialized expertise, and are typically confined to centralized core facilities, creating analytical delays.

Abselion's Amperia™ system charts a middle path, promising the speed and simplicity of a benchtop instrument with the quality of more complex methods. Built on proprietary Redox Electrochemical Detection (RED) technology, the compact device converts biochemical interactions on a disposable sensor strip into a precise electrical signal. This approach eliminates the need for the complex optics and fluidics that characterize other systems. The result is a platform that can deliver what the company calls "gold-standard insights in minutes," dramatically reducing hands-on time and the potential for human error. For researchers developing next-generation therapies, this acceleration is critical. Faster quantification means faster decision-making, enabling researchers to more quickly identify promising drug candidates, optimize manufacturing processes, and ultimately shorten the long road from lab to clinic.

The 'Tough Tech' Advantage at MIT's The Engine

Abselion's choice of The Engine as its American launchpad is as strategic as the technology it hopes to deploy. Founded by MIT in 2016, The Engine is not a typical startup incubator. It was purpose-built to support 'Tough Tech'—companies built on breakthrough science and engineering that often require significant physical infrastructure, long development timelines, and patient capital to succeed. This philosophy makes it an ideal home for a company like Abselion, whose innovation is rooted in hardware and advanced material science.

The Engine provides its portfolio companies with more than just a prestigious Cambridge address. It offers over 200,000 square feet of specialized infrastructure, including the Biosafety Level 2 (BSL-2) wet labs essential for life science research. More importantly, it provides an unparalleled ecosystem of mentorship, networking, and capital. The incubator’s fund has an unusually long eighteen-year lifespan, reflecting an understanding that deep-tech innovation cannot be rushed. By joining this community, Abselion gains a powerful ally in navigating the US market, with direct connections to investors, academics, public officials, and corporate partners who understand the unique challenges and massive potential of its field.

For The Engine, attracting a promising international company like Abselion validates its role as a global gateway for innovation. It demonstrates how such ecosystems can foster cross-border technology transfer, creating a synergistic environment where a UK-developed platform can be refined and scaled through close collaboration with leading researchers and companies in the US.

Navigating a Competitive Landscape

Despite its innovative technology and strategic positioning, Abselion faces a formidable challenge. The North American protein detection and quantification market, which held a 37.2% share of the $2.68 billion global market in 2023, is dominated by established life science giants like Thermo Fisher Scientific, Bio-Rad Laboratories, and Danaher Corporation. These incumbents have vast resources, extensive product portfolios, and deeply entrenched customer relationships.

To succeed, Abselion must effectively communicate its unique value proposition. Its competitive edge lies in a powerful combination of speed, simplicity, and accessibility that directly addresses the unmet needs of modern biologics R&D. The market is expanding rapidly, with projections estimating it will reach $4.83 billion by 2030, driven by the growth in proteomics research and personalized medicine. This growth creates openings for disruptive technologies that can improve efficiency and reduce costs.

By establishing a physical presence in Cambridge, Abselion is positioning itself to seize this opportunity. The new subsidiary will serve as a crucial hub for sales, application support, and collaboration, allowing the company's team to work directly with scientists to integrate the Amperia™ platform into their workflows. Proximity to potential customers is paramount for demonstrating the system's capabilities and building the trust needed to win over researchers from established methods. The journey ahead is demanding, but by planting its roots in the fertile ground of The Engine, Abselion has given itself the best possible chance to flourish in the competitive American market.